The present application relates to a medical hydrogel comprising nanofibrillar cellulose, wherein the hydrogel has a viscosity in the range of 2500-9000 Pa.Math.s and a water retention value in the range of 30-100 g/g. The present application also relates to a method for preparing the medical hydrogel The present application relates to the medical hydrogel for use for treating wounds.

The present invention relates to nucleic acids of the general formula (I): (N.sub.uG.sub.lX.sub.mG.sub.nN.sub.v).sub.a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (N.sub.uG.sub.lX.sub.mG.sub.nN.sub.v).sub.a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

A compound for use in the treatment of itch is provided, wherein the compound comprises the general formula (1a), general formula (1b) or general formula (1c). The compounds of the invention are positive allosteric α2 and/or α3 GABA.sub.A receptor modulators.

A compound for use in the treatment of itch is provided, wherein the compound comprises the general formula (1a), general formula (1b) or general formula (1c). The compounds of the invention are positive allosteric α2 and/or α3 GABA.sub.A receptor modulators.

Compositions comprising microbiome regulators are provided, as well as methods of using the same for the modulation of the human microbiota and to treat or prevent related diseases, disorders, or conditions.

The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.

A transdermal patch is provided, wherein the patch comprises a cross-linked poly(ethylene oxide) hydrogel loaded with naltrexone, or a pharmaceutically acceptable salt or solvate thereof, and an occlusive adhesive tape. The poly(ethylene oxide) hydrogel has a crosslink density of at least 4.5×10.sup.−4 mol cm.sup.−3 and not more than 16×10.sup.−4 mol cm.sup.−3. Also provided are methods for preparing naltrexone-loaded cross-linked poly(ethylene oxide) hydrogels, transdermal patches for use as a medicament, for example in the treatment of a specified condition with LDN therapy.

The present disclosure provides an animal food composition comprising a source of glycyrrhizin, in combination with a source of curcuminoids, for use for preventing and/or treating allergic inflammatory skin diseases.

The present disclosure provides an animal food composition comprising a source of glycyrrhizin, in combination with a source of curcuminoids, for use for preventing and/or treating allergic inflammatory skin diseases.